Država: Sjedinjene Američke Države
Jezik: engleski
Izvor: NLM (National Library of Medicine)
ATAZANAVIR SULFATE (UNII: 4MT4VIE29P) (ATAZANAVIR - UNII:QZU4H47A3S), COBICISTAT (UNII: LW2E03M5PG) (COBICISTAT - UNII:LW2E03M5PG)
E.R. Squibb & Sons, L.L.C.
ATAZANAVIR SULFATE
ATAZANAVIR 300 mg
ORAL
PRESCRIPTION DRUG
EVOTAZ® is indicated in combination with other antiretroviral agents for the treatment of human immunodeficiency virus (HIV-1) infection in the following populations [see Dosage and Administration (2.2, 2.3)] : Use of EVOTAZ in treatment-experienced patients should be guided by the number of baseline primary protease inhibitor resistance substitutions [see Clinical Pharmacology (12.4) ] . The concomitant use of EVOTAZ and the following drugs in Table 1, are contraindicated due to the potential for serious and/or life-threatening events or loss of therapeutic effect [see Warnings and Precautions (5.8, 5.9), Drug Interactions (7), and Clinical Pharmacology (12.3)]. EVOTAZ is contraindicated: Table 1: Drugs Contraindicated with EVOTAZ Alpha 1-adrenoreceptor antagonist alfuzosin Antianginal ranolazine Antiarrhythmics dronedarone Anticonvulsants carbamazepine, phenobarbital, phenytoin Antigout colchicine (when used in patients with hepatic and/or renal impairment) Antimycobacterials rifampin Antineoplastics irino
EVOTAZ® tablets, 300 mg atazanavir and 150 mg cobicistat, are oval, biconvex, pink, film-coated, debossed with “3641” on one side and plain on the other side. Each bottle contains 30 tablets (NDC-0003-3641-11), a silica gel desiccant and is closed with a child-resistant closure. Store EVOTAZ tablets at 25°C (77°F); excursions permitted between 15°C and 30°C (59°F and 86°F) [see USP Controlled Room Temperature]. Keep container tightly closed.
New Drug Application
EVOTAZ- ATAZANAVIR AND COBICISTAT TABLET E.R. SQUIBB & SONS, L.L.C. ---------- HIGHLIGHTS OF PRESCRIBING INFORMATION THESE HIGHLIGHTS DO NOT INCLUDE ALL THE INFORMATION NEEDED TO USE EVOTAZ SAFELY AND EFFECTIVELY. SEE FULL PRESCRIBING INFORMATION FOR EVOTAZ. EVOTAZ (ATAZANAVIR AND COBICISTAT) TABLET, FOR ORAL USE INITIAL U.S. APPROVAL: 2015 INDICATIONS AND USAGE EVOTAZ is a two-drug combination of atazanavir, a human immunodeficiency virus (HIV-1) protease inhibitor, and cobicistat, a CYP3A inhibitor indicated for use in combination with other antiretroviral agents for the treatment of HIV‑1 infection in adults and pediatric patients weighing at least 35 kg. (1) _Limitations of Use_ Use of EVOTAZ in treatment-experienced patients should be guided by the number of baseline primary protease inhibitor resistance substitutions. (1) DOSAGE AND ADMINISTRATION • • • • DOSAGE FORMS AND STRENGTHS • CONTRAINDICATIONS • • WARNINGS AND PRECAUTIONS • • • • • • ® _Pretreatment testing: _Renal laboratory testing should be performed in all patients prior to initiation of EVOTAZ and continued during treatment with EVOTAZ. Hepatic testing should be performed in patients with underlying liver disease prior to initiation of EVOTAZ and continued during treatment with EVOTAZ. (2.1) _Recommended dosage:_ One tablet once daily, taken orally with food in adults and pediatric patients weighing at least 35 kg. (2.2) _Renal impairment:_ EVOTAZ is not recommended for use in treatment-experienced patients with end- stage renal disease managed with hemodialysis. (2.3, 8.6) _Hepatic impairment:_ EVOTAZ is not recommended in patients with any degree of hepatic impairment. (2.4, 8.7) Tablets: 300 mg of atazanavir and 150 mg of cobicistat. (3) EVOTAZ is contraindicated in patients with previously demonstrated hypersensitivity (e.g., Stevens- Johnson syndrome, erythema multiforme, or toxic skin eruptions) to any of the components of this product. (4) Coadministration with certain drugs for which altered plasma concentra Pročitajte cijeli dokument